Antisense Therapeutics is developing an advanced stage pipeline of second-generation antisense drugs. Its lead compounds are in Phase 2 clinical development with near-term milestones acting on validated targets in acromegaly and multiple sclerosis.
It has a partnership and worldwide licensing agreement with Isis Pharmaceuticals.
Wish ISIS had put up some cash! then Booooooooooooooom goes the gasman!
Still sentiment holding until a rumours may drive up the SP 10/15%...just over 10c...Maybe another buy on rumour sell on fact, the ANP way! 30c....hmmm thats a long way off!
ANP Price at posting:
9.0¢ Sentiment: Buy Disclosure: Held
